CN115515588A - 大环ulk1/2抑制剂 - Google Patents

大环ulk1/2抑制剂 Download PDF

Info

Publication number
CN115515588A
CN115515588A CN202180027809.1A CN202180027809A CN115515588A CN 115515588 A CN115515588 A CN 115515588A CN 202180027809 A CN202180027809 A CN 202180027809A CN 115515588 A CN115515588 A CN 115515588A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
independently
heterocycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027809.1A
Other languages
English (en)
Chinese (zh)
Inventor
尼古拉斯·D·P·科斯福德
尼科尔·A·巴卡斯
鲁本·J·肖
艾莉森·S·林佩特
索尼亚·N·布伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandford Burnham Preby Institute For Medical Discovery
Salk Institute for Biological Studies
Original Assignee
Sandford Burnham Preby Institute For Medical Discovery
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandford Burnham Preby Institute For Medical Discovery, Salk Institute for Biological Studies filed Critical Sandford Burnham Preby Institute For Medical Discovery
Publication of CN115515588A publication Critical patent/CN115515588A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180027809.1A 2020-02-14 2021-02-12 大环ulk1/2抑制剂 Pending CN115515588A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977039P 2020-02-14 2020-02-14
US62/977,039 2020-02-14
PCT/US2021/018038 WO2021163627A1 (en) 2020-02-14 2021-02-12 Macrocyclic ulk1/2 inhibitors

Publications (1)

Publication Number Publication Date
CN115515588A true CN115515588A (zh) 2022-12-23

Family

ID=77292762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027809.1A Pending CN115515588A (zh) 2020-02-14 2021-02-12 大环ulk1/2抑制剂

Country Status (8)

Country Link
US (1) US12594277B2 (https=)
EP (1) EP4103183A4 (https=)
JP (1) JP2023513793A (https=)
KR (1) KR20220153582A (https=)
CN (1) CN115515588A (https=)
AU (1) AU2021221162A1 (https=)
CA (1) CA3171185A1 (https=)
WO (1) WO2021163627A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159556A1 (en) * 2020-04-20 2023-05-25 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2022072668A1 (en) * 2020-09-30 2022-04-07 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors
TW202404979A (zh) * 2022-07-18 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抑制並誘導ｅｇｆｒ降解的大環類化合物、其製備方法及其在醫藥上的應用
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2024233766A1 (en) * 2023-05-10 2024-11-14 Erasca, Inc. Macrocyclic ulk1/2 inhibitors and their use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
US20190284207A1 (en) * 2014-08-25 2019-09-19 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
EP1794135A1 (en) 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2007028445A1 (en) 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
JP5161233B2 (ja) 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
JP2010523639A (ja) 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
WO2008140421A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Heterocycloalkyl substituted pyrimidine derivatives
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
WO2009083185A2 (en) 2007-12-28 2009-07-09 Fovea Pharmaceuticals Sa Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
EP2274288A2 (en) * 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2009262198B2 (en) 2008-06-25 2012-09-27 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2942392B1 (en) * 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
CA2763720A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US20130040310A1 (en) * 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
CN102792160B (zh) 2010-01-08 2015-08-19 新加坡科技研究局 用于治疗癌症的方法和组合物
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012040602A2 (en) 2010-09-23 2012-03-29 President And Fellows Of Harvard College Targeting mtor substrates in treating proliferative diseases
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
CA2864394C (en) 2011-03-02 2021-10-19 Jack Roth A method of predicting a response to a tusc2 therapy
CN103458970A (zh) 2011-03-07 2013-12-18 泰莱托恩基金会 Tfeb磷酸化抑制剂及其应用
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
US9073944B2 (en) 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014098932A1 (en) 2012-12-17 2014-06-26 The Brigham And Women's Hosptial, Inc. Treatment of mtor hyperactive related diseases and disorders
CN103059030B (zh) 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
EP3473299A1 (en) 2013-06-05 2019-04-24 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
US10300058B2 (en) 2014-04-18 2019-05-28 Xuanzhu Pharma Co., Ltd. Tyrosine kinase inhibitor and uses thereof
EP3159338A4 (en) 2014-06-17 2018-01-24 Korea Research Institute of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
CN105524045B (zh) 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
US20160159774A1 (en) 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106188029B (zh) 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
AU2017346845B2 (en) 2016-10-18 2021-12-02 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders
WO2018102366A1 (en) 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
JP6684700B2 (ja) 2016-12-26 2020-04-22 アイシン精機株式会社 乗員検知装置
CN110831937A (zh) 2017-05-02 2020-02-21 韩国化学研究院 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
KR20220154094A (ko) 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
KR20220153581A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 의 억제제 및 이의 사용 방법
US20230159556A1 (en) * 2020-04-20 2023-05-25 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2022072668A1 (en) 2020-09-30 2022-04-07 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190284207A1 (en) * 2014-08-25 2019-09-19 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof

Also Published As

Publication number Publication date
WO2021163627A1 (en) 2021-08-19
CA3171185A1 (en) 2021-08-19
AU2021221162A1 (en) 2022-09-22
US12594277B2 (en) 2026-04-07
JP2023513793A (ja) 2023-04-03
US20230099804A1 (en) 2023-03-30
KR20220153582A (ko) 2022-11-18
EP4103183A1 (en) 2022-12-21
EP4103183A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN115515588A (zh) 大环ulk1/2抑制剂
RU2719428C2 (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
CN115232129B (zh) 一种parp1选择性抑制剂及其制备方法和用途
CN117157292A (zh) Kras g12d抑制剂和其用途
CN109311894B (zh) 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物
AU2015266453C1 (en) Alk kinase inhibitor, and preparation method and use thereof
CN104066735B (zh) 作为akt激酶抑制剂的取代的咪唑并吡嗪
CA2830367A1 (en) Novel imidazo-oxazine compound or salt thereof
WO2025045106A1 (zh) 一种PI3Kα抑制剂及其用途
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
CN115515589A (zh) Ulk1/2抑制剂及其使用方法
CN104603134A (zh) 酰氨基-苄基砜和亚砜衍生物
EP3496724B1 (en) Protein kinase regulators
CN114621231A (zh) 一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
JPWO2020032105A1 (ja) 光学活性な架橋型ピペリジン誘導体
WO2017191599A1 (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
EP3705480A1 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
CN103313599A (zh) 取代的4-(芳基氨基)硒吩并嘧啶化合物及其使用方法
EP3805212A1 (en) 3-oxazolinone compound, preparation method therefor and pharmaceutical application thereof
EP4126842B1 (en) Trka inhibitor
KR20240041340A (ko) 피롤로피리미딘 유도체 화합물 및 이의 용도
WO2020233716A1 (zh) 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
CN120058674A (zh) 4（1h-吡唑-3-基）哌啶基衍生物及其制备方法与在制备mnk抑制剂中的应用
CN118434743A (zh) 三环杂环类
WO2026067457A1 (zh) 作为pkmyt1抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221223

WD01 Invention patent application deemed withdrawn after publication